BiotechTube

Trastuzumab emtansine

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

Conditions

HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

Trial Timeline

Nov 1, 2016 → Dec 14, 2019

NCT ID
NCT02658734

About Trastuzumab emtansine

Trastuzumab emtansine is a approved stage product being developed by Roche for HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02658734. Target conditions include HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer.

What happened to similar drugs?

0 of 20 similar drugs in HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer were approved

Approved (0) Terminated (1) Active (19)
🔄TrastuzumabCelltrionPhase 3
🔄Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
🔄Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + TrastuzumabDaiichi SankyoPhase 3
🔄DS-8201a + T-DM1Daiichi SankyoPhase 3
🔄E7389 (Eribulin Mesylate) + Vinorelbine injectionEisaiPhase 3
❌PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxelBioconPhase 3
🔄SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel InjectionJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (10)

NCT IDPhaseStatus
NCT06595563Phase 2Recruiting
NCT05945927Pre-clinicalCompleted
NCT05754502Pre-clinicalUNKNOWN
NCT03153163Phase 1Completed
NCT02999672Phase 2Completed
NCT02658734ApprovedCompleted
NCT02289833Phase 2Completed
NCT01702571Phase 3Completed
NCT01513083Phase 1Completed
NCT01196052Phase 2Completed

Competing Products

20 competing products in HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

See all competitors
ProductCompanyStageHype Score
ALT-P7 (HM2-MMAE)AlteogenPhase 1
29
CT-0508 + PembrolizumabCarisma TherapeuticsPhase 1
23
CT-0525Carisma TherapeuticsPhase 1
23
TrastuzumabCelltrionPhase 3
40
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
40
YH32367YuhanPhase 1/2
39
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
33
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
26
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
33
Trastuzumab deruxtecan (T-DXd)Daiichi SankyoPre-clinical
33
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42
Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + TrastuzumabDaiichi SankyoPhase 3
44
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
DS-8201a + T-DM1Daiichi SankyoPhase 3
44
Enzalutamide + TrastuzumabAstellas PharmaPhase 2
35
E7389 (Eribulin Mesylate) + Vinorelbine injectionEisaiPhase 3
40
Durvalumab + EribulinEisaiPhase 1
29
Eribulin + Cyclophosphamide + DocetaxelEisaiPhase 2
35
Pertuzumab + Trastuzumab + eribulinEisaiPhase 2
27